Determination Concerning a Petition To Add a Class of Employees to the Special Exposure Cohort, 59626 [2017-27039]
Download as PDF
<![CDATA[
59626
Federal Register / Vol. 82, No. 240 / Friday, December 15, 2017 / Notices
or other forms of information
technology to minimize the information
collection burden.
Amy McNulty,
Acting Director, Division of the Executive
Secretariat.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
[FR Doc. 2017–27013 Filed 12–14–17; 8:45 am]
ACTION:
BILLING CODE 4165–15–P
Findings of research
misconduct have been made on the part
of Matthew Endo, former graduate
student, Department of Chemistry,
University of Illinois at UrbanaChampaign. The questioned research
was supported by National Institute of
General Medical Sciences (NIGMS),
National Institutes of Health (NIH),
grant R01 GM080436. The
administrative actions, including three
(3) years of supervision, which are
implemented beginning on November
16, 2017, are detailed below.
FOR FURTHER INFORMATION CONTACT:
Wanda K. Jones, Dr.P.H., Interim
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8200.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that the Office of Research
Integrity (ORI) has taken final action in
the following case:
Matthew Endo, University of Illinois
at Urbana-Champaign: Based on the
Respondent’s admission, an assessment
conducted by University of Illinois at
Urbana-Champaign (UIUC), and analysis
conducted by ORI in its oversight
review, ORI found that Mr. Matthew
Endo, a former graduate student,
Department of Chemistry, UIUC,
engaged in research misconduct in
research supported by National Institute
of General Medical Sciences (NIGMS),
National Institutes of Health (NIH),
grant R01 GM080436.
ORI found that Respondent engaged
in research misconduct by intentionally,
knowingly, or recklessly causing false
data to be recorded, falsifying and/or
fabricating data and related images by
alteration and/or reuse and/or relabeling
of experimental data, and reporting
falsified and/or fabricated data in one
(1) manuscript subsequently submitted
for publication:
• ‘‘Amphotericin primarily kills human
cells by binding and extracting
cholesterol.’’ Submitted for
publication to the Proceedings of the
National Academy of Sciences
[withdrawn prior to peer review]
(hereafter referred to as ‘‘Manuscript
1’’)
SUMMARY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Determination Concerning a Petition
To Add a Class of Employees to the
Special Exposure Cohort
National Institute for
Occupational Safety and Health
(NIOSH), Centers for Disease Control
and Prevention, Department of Health
and Human Services (HHS).
AGENCY:
ACTION:
Notice.
HHS gives notice of a
determination concerning a petition to
add a class of employees from the
Carborundum Company, in Niagara
Falls, New York, to the Special
Exposure Cohort (SEC) under the Energy
Employees Occupational Illness
Compensation Program Act of 2000
(EEOICPA).
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Stuart L. Hinnefeld, Director, Division
of Compensation Analysis and Support,
National Institute for Occupational
Safety and Health (NIOSH), 1090
Tusculum Avenue, MS C–46,
Cincinnati, OH 45226–1938, Telephone
1–877–222–7570. Information requests
can also be submitted by email to
DCAS@CDC.GOV.
SUPPLEMENTARY INFORMATION:
Authority: [42 U.S.C.7384q].
sradovich on DSK3GMQ082PROD with NOTICES
On November 16, 2017, the Acting
Secretary of HHS determined that the
following class of employees does not
meet the statutory criteria for addition
to the SEC as authorized under
EEOICPA:
All employees who worked in any area of
the Carborundum Company facility on
Buffalo Avenue, Niagara Falls, New York,
from January 1, 1943, through December 31,
1976.
John Howard,
Director, National Institute for Occupational
Safety and Health.
[FR Doc. 2017–27039 Filed 12–14–17; 8:45 am]
BILLING CODE 4163–19–P
VerDate Sep<11>2014
23:42 Dec 14, 2017
Jkt 244001
Specifically, ORI found that:
• In Manuscript 1, Respondent caused
falsified and/or fabricated results to
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
be recorded by knowingly requesting
biological testing of a mixture of
compounds that he falsely claimed to
be a single compound
• In Manuscript 1, Respondent falsified
and/or fabricated the results on page
S26 of the Supporting Information by
modifying the HPLC trace through
peak erasure to make the preparation
of C35deOAmB appear more pure
than in the actual results of
experimentation
• In Manuscript 1, Respondent falsified
and/or fabricated the results of
Surface Plasmon Resonance data on
page S7 of the Supporting Information
to make the error bars smaller than
the actual results of experimentation
• In Manuscript 1, Respondent falsified
and/or fabricated the results of a
WST08 Cell Proliferation Assay on
page S32 of the Supporting
Information by falsely claiming to run
the reaction in triplicate when it was
only performed in duplicate
• In correspondence with his advisor,
Respondent falsified and/or fabricated
the results of the preparation of
putative C2deoAmB where
Respondent modified and relabeled a
HPLC trace and relabeled an NMR
spectrum to falsely claim
characterization, purity, and
identification of sample that was sent
for biological assay
Mr. Endo entered into a Voluntary
Settlement Agreement and voluntarily
agreed for a period of three (3) years,
beginning on November 16, 2017:
(1) To have his research supervised;
Respondent agreed to ensure that prior
to the submission of an application for
PHS support for a research project on
which Respondent’s participation is
proposed and prior to Respondent’s
participation in any capacity on PHSsupported research, the institution
employing him must submit a plan for
supervision of Respondent’s duties to
ORI for approval; the plan for
supervision must be designed to ensure
the scientific integrity of Respondent’s
research contribution; Respondent
agreed that he will not participate in
any PHS-supported research until a plan
for supervision is submitted and
approved by ORI;
(2) that any institution employing him
must submit in conjunction with each
application for PHS funds, or report,
manuscript, or abstract involving PHS
supported research in which
Respondent is involved, a certification
to ORI that the data provided by
Respondent are based on actual
experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
E:\FR\FM\15DEN1.SGM
15DEN1
]]>Agencies
[Federal Register Volume 82, Number 240 (Friday, December 15, 2017)]
[Notices]
[Page 59626]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-27039]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Determination Concerning a Petition To Add a Class of Employees
to the Special Exposure Cohort
AGENCY: National Institute for Occupational Safety and Health (NIOSH),
Centers for Disease Control and Prevention, Department of Health and
Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: HHS gives notice of a determination concerning a petition to
add a class of employees from the Carborundum Company, in Niagara
Falls, New York, to the Special Exposure Cohort (SEC) under the Energy
Employees Occupational Illness Compensation Program Act of 2000
(EEOICPA).
FOR FURTHER INFORMATION CONTACT: Stuart L. Hinnefeld, Director,
Division of Compensation Analysis and Support, National Institute for
Occupational Safety and Health (NIOSH), 1090 Tusculum Avenue, MS C-46,
Cincinnati, OH 45226-1938, Telephone 1-877-222-7570. Information
requests can also be submitted by email to [email protected].
SUPPLEMENTARY INFORMATION:
Authority: [42 U.S.C.7384q].
On November 16, 2017, the Acting Secretary of HHS determined that
the following class of employees does not meet the statutory criteria
for addition to the SEC as authorized under EEOICPA:
All employees who worked in any area of the Carborundum Company
facility on Buffalo Avenue, Niagara Falls, New York, from January 1,
1943, through December 31, 1976.
John Howard,
Director, National Institute for Occupational Safety and Health.
[FR Doc. 2017-27039 Filed 12-14-17; 8:45 am]
BILLING CODE 4163-19-P
